IL192207A0 - Chimeric and humanised anti-human il -13 antibodies - Google Patents

Chimeric and humanised anti-human il -13 antibodies

Info

Publication number: IL192207A0
Authority: IL; Israel
Prior art keywords: chimeric; antibodies; human; humanised anti; humanised
Prior art date: 2006-01-11

Application number

IL192207A

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-11

Filing date

2008-06-16

Publication date

2008-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL192207(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-16 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-12-29 Publication of IL192207A0 publication Critical patent/IL192207A0/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Neurology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

IL192207A 2006-01-11 2008-06-16 Chimeric and humanised anti-human il -13 antibodies IL192207A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0600488.1A GB0600488D0 (en)	2006-01-11	2006-01-11	Immunoglobulins
PCT/EP2007/050219 WO2007080174A2 (en)	2006-01-11	2007-01-10	Chimeric and humanised anti-human il-13 antibodies

Publications (1)

Publication Number	Publication Date
IL192207A0 true IL192207A0 (en)	2008-12-29

Family

ID=35997844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL192207A IL192207A0 (en)	2006-01-11	2008-06-16	Chimeric and humanised anti-human il -13 antibodies

Country Status (18)

Country	Link
EP (1)	EP1976881A2 (en)
JP (1)	JP2009523154A (en)
KR (1)	KR20080113201A (en)
CN (1)	CN101370829A (en)
AR (1)	AR058955A1 (en)
AU (1)	AU2007204372A1 (en)
BR (1)	BRPI0706481A2 (en)
CA (1)	CA2635972A1 (en)
CR (1)	CR10161A (en)
EA (1)	EA200801520A1 (en)
GB (1)	GB0600488D0 (en)
IL (1)	IL192207A0 (en)
MA (1)	MA30156B1 (en)
NO (1)	NO20082767L (en)
PE (1)	PE20081185A1 (en)
TW (1)	TW200736274A (en)
WO (1)	WO2007080174A2 (en)
ZA (1)	ZA200805526B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2532679B1 (en)	2005-10-21	2017-04-12	Novartis AG	Human antibodies against il13 and therapeutic uses
SG172625A1 (en)	2006-05-25	2011-07-28	Glaxo Group Ltd	Modified humanised anti-interleukin-18 antibodies
EP2050764A1 (en) *	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
US20110236380A1 (en) *	2008-11-26	2011-09-29	De Wildt Rudolf M T	Ligands that bind il-13
JP5836807B2 (en) *	2009-03-05	2015-12-24	アッヴィ・インコーポレイテッド	IL-17 binding protein
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
US8680245B2 (en)	2009-05-28	2014-03-25	Glaxo Group Limited	IL-13 binding protein
CN102711828B (en)	2009-10-20	2015-06-17	Abbvie公司	Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
ES2645368T3 (en) *	2010-10-15	2017-12-05	Medimmune Limited	Therapies to improve lung function
CN103688171B (en)	2010-12-16	2017-10-24	弗·哈夫曼-拉罗切有限公司	The diagnosis and treatment related to TH2 suppression
TWI719112B (en)	2011-03-16	2021-02-21	賽諾菲公司	Uses of a dual v region antibody-like protein
BR112016008694A2 (en)	2013-10-23	2017-10-03	Genentech Inc	METHODS FOR PREDICTING THE REACTION OF PATIENTS WITH ASTHMA, FOR PREDICTING THE ABILITY TO REACT IN PATIENTS WITH ASTHMA, FOR IDENTIFYING PATIENTS WITH ASTHMA, FOR TREATMENT OF PATIENTS WITH ASTHMA AND FOR TREATMENT OF ASTHMA, USE OF A KIT AND KIT
MX2016010729A (en)	2014-02-21	2016-10-26	Genentech Inc	Anti-il-13/il-17 bispecific antibodies and uses thereof.
US10066267B2 (en)	2014-04-11	2018-09-04	Novartis Ag	Methods of selectively treating asthma using IL-13 antagonists
KR20170127011A (en)	2015-03-16	2017-11-20	제넨테크, 인크.	Methods for detecting and quantifying IL-13 and for diagnosing and treating TH2-related diseases
US20190086392A1 (en)	2016-03-21	2019-03-21	Inserm (Institut National De La Sante Et De La Recherch Medicale)	Methods for diagnosis and treatment of solar lentigo
CN114617962A (en)	2016-04-27	2022-06-14	艾伯维公司	Methods of using anti-IL-13 antibodies to treat diseases in which IL-13 activity is detrimental
CN110198956A (en) *	2017-01-23	2019-09-03	学校法人东洋大学	Anti-EPHA 2 antibody and the EPHA2 immune detection for using the anti-EPHA 2 antibody
CN109776677B (en) *	2017-11-15	2023-11-03	尚华科创投资管理（江苏）有限公司	Humanized anti-IL-13 antibody and preparation method and application thereof
CN107909501B (en) *	2017-12-05	2020-12-01	创新先进技术有限公司	Smell and behavior association method, smell social method and device
BR112020016172A2 (en)	2018-02-09	2020-12-15	Genentech, Inc.	TREATMENT METHODS, METHODS FOR DETERMINING, METHODS FOR SELECTING A THERAPY, METHODS FOR EVALUATING A RESPONSE AND MONITORING THE RESPONSE, KITS FOR IDENTIFYING A PATIENT, SELECTED AGENTS, AGENTS FOR USE, USE OF A SELECTED AGENT AND USE OF A SELECTED AGENT
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
JP2022525703A (en) *	2019-03-20	2022-05-18	ジャベリン・オンコロジー・インコーポレイテッド	Anti-ADAM12 antibody and chimeric antigen receptor, and compositions and methods comprising them.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003260748A1 (en) *	2002-08-30	2004-03-19	Glaxo Group Limited	Il-14 vaccine for the treatment of asthma and atopic disorders
WO2004096849A2 (en) *	2003-04-25	2004-11-11	University Of Manitoba	Peptide-based cytokine/chemokine vaccines against allergy
KR20150064250A (en) *	2003-12-23	2015-06-10	제넨테크, 인크.	Novel anti-il 13 antibodies and uses thereof
US7501121B2 (en) *	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
TWI307630B (en) *	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins

2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
2007
- 2007-01-09 TW TW096100833A patent/TW200736274A/en unknown
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/en not_active Application Discontinuation
- 2007-01-09 AR ARP070100082A patent/AR058955A1/en unknown
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/en not_active Application Discontinuation
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/en active Pending
- 2007-01-10 EP EP07703766A patent/EP1976881A2/en not_active Withdrawn
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/en not_active IP Right Cessation
- 2007-01-10 CA CA002635972A patent/CA2635972A1/en not_active Abandoned
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/en active Application Filing
- 2007-01-10 EA EA200801520A patent/EA200801520A1/en unknown
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/en active Pending
2008
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-16 NO NO20082767A patent/NO20082767L/en not_active Application Discontinuation
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/en unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/en unknown
- 2008-07-17 CR CR10161A patent/CR10161A/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
TW200736274A (en)	2007-10-01
CN101370829A (en)	2009-02-18
BRPI0706481A2 (en)	2011-03-29
ZA200805526B (en)	2009-10-28
EP1976881A2 (en)	2008-10-08
AU2007204372A1 (en)	2007-07-19
NO20082767L (en)	2008-10-06
MA30156B1 (en)	2009-01-02
CR10161A (en)	2008-11-26
AR058955A1 (en)	2008-03-05
WO2007080174A2 (en)	2007-07-19
CA2635972A1 (en)	2007-07-19
WO2007080174A3 (en)	2007-12-06
JP2009523154A (en)	2009-06-18
KR20080113201A (en)	2008-12-29
EA200801520A1 (en)	2009-02-27
PE20081185A1 (en)	2008-10-07
GB0600488D0 (en)	2006-02-22

Publication	Publication Date	Title
IL192207A0 (en)	2008-12-29	Chimeric and humanised anti-human il -13 antibodies
IL180152A0 (en)	2007-06-03	Chimeric and humanised monoclonal antibodies against inteleukin-13
IL239947A (en)	2016-03-31	Anti-human il-21 monoclonal antibodies
IL194995A0 (en)	2011-08-01	Modified humanised anti-interleukin-18 antibodies
ZA200810381B (en)	2010-03-31	Antagonistic anti-human CD40 monoclonal antibody
IL202232A0 (en)	2010-06-16	Novel rabbit antibody humanization methods and humanized rabbit antibodies
ZA201004752B (en)	2011-04-28	Humanized anti-human nkg2a monoclonal antibody
HK1199047A1 (en)	2015-06-19	Il-31 monoclonal antibodies and methods of use il-31
ZA201008993B (en)	2012-01-25	Anti-human interleukin-20 antibodies
EP2021029A4 (en)	2010-01-06	Humanized fc riib-specific antibodies and methods of use thereof
IL196550A0 (en)	2011-08-01	Anti-il-6 monoclonal antibodies and uses thereof
IL193871A0 (en)	2011-08-01	Humanized anti-cd20 monoclonal antibody
EP2016162A4 (en)	2009-11-11	Humanized monoclonal antibodies to hepatocyte growth factor
EP1998807A4 (en)	2010-02-17	Methods for humanizing antibodies and humanized antibodies made thereby
HK1100848A1 (en)	2007-09-28	Anti-human tenascin monoclonal antibody
SI1899377T1 (en)	2012-12-31	Humanised antibodies specific for nogo-a and phrarmaceutical uses thereof
IL206898A0 (en)	2010-12-30	HUMANIZED ANTI-HUMAN a9-INTEGRIN ANTIBODY AND USES THEREOF
EP2322610A4 (en)	2012-12-12	Anti-human clcp1 antibody and use thereof